Skip to main content

Table 6 The sensitivity analysis at 45% sharing rate for cumulative annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Variables

Annual cost of operation

Sharing rate

# of HIV averted

# of HCV averted

HIV cost saved

HCV cost saved

Cost-effectiveness ratio HCV

Cost-effectiveness ratio HIV

Cost-benefit ratio HCV

Cost-benefit ratio HIV

Post SIF

$2,182,800

45%

19

115

$1,817,745

$1,858,645

$18,980

$114,884

1.85

1.8

Two SIF

$4,365,600

35%

35

214

$3,003,825

$3,155,002

$20,400

$124,731

1.7

1.7

Three SIF

$6,548,400

27%

42

256

$2,294,910

$2,448,208

$25,580

$155,914

1.4

1.4

Four SIF

$8,731,200

23%

49

299

$1,585,995

$1,776,557

$29,201

$178,188

1.2

1.2

Five SIF

$10,914,000

20%

56

341

$877,080

$1,069,763

$32,006

$194,893

1.1

1.1

Six SIF

$13,096,800

16.00%

63

384

$168,165

$398,112

$34,106

$207,886

1

1

Seven SIF

$15,279,600

12%

70

427

-$540,750

-$273,539

$35,784

$218,280

0.96

0.98

Average

$8,731,200

9%

48

291

$1,375,440

$1,495,413

$30,004

$181,900

1.16

1.17